Medy Tox Inc
KOSDAQ:086900
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Medy Tox Inc
KOSDAQ:086900
|
KR |
|
Naver Corp
KRX:035420
|
KR |
|
Southern Petrochemical Industries Corporation Ltd
NSE:SPIC
|
IN |
|
Bexil Corp
OTC:BXLC
|
US |
|
C
|
Cargotec Corp
SWB:C1C
|
FI |
|
T
|
Telomir Pharmaceuticals Inc
NASDAQ:TELO
|
US |
|
China Reform Culture Holdings Co Ltd
SSE:600636
|
CN |
|
British American Tobacco PLC
LSE:BATS
|
UK |
|
S
|
SPK Corp
TSE:7466
|
JP |
|
F
|
Form Bio Co Ltd
KOSDAQ:377220
|
KR |
|
Stallion Uranium Corp
OTC:STLNF
|
CA |
Wall Street
Price Targets
Price Targets Summary
Medy Tox Inc
According to Wall Street analysts, the average 1-year price target for Medy Tox Inc is 121 720 KRW with a low forecast of 90 900 KRW and a high forecast of 155 400 KRW.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Medy Tox Inc's stock price target?
Price Target
121 720
KRW
According to Wall Street analysts, the average 1-year price target for Medy Tox Inc is 121 720 KRW with a low forecast of 90 900 KRW and a high forecast of 155 400 KRW.
What is Medy Tox Inc's Revenue forecast?
Projected CAGR
14%
For the last 12 years the compound annual growth rate for Medy Tox Inc's revenue is 17%. The projected CAGR for the next 2 years is 14%.
What is Medy Tox Inc's Operating Income forecast?
Projected CAGR
90%
For the last 12 years the compound annual growth rate for Medy Tox Inc's operating income is 0%. The projected CAGR for the next 2 years is 90%.
What is Medy Tox Inc's Net Income forecast?
Projected CAGR
98%
For the last 12 years the compound annual growth rate for Medy Tox Inc's net income is 1%. The projected CAGR for the next 2 years is 98%.
